J Korean Med Sci.  2009 Apr;24(2):242-247. 10.3346/jkms.2009.24.2.242.

The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size

• Choi SB
• Kim KS
• Park YN
• Choi JS
• Lee WJ
• Seong J
• Han KH
• Lee JT

• KMID: 1779125
• DOI: http://doi.org/10.3346/jkms.2009.24.2.242

Abstract

In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study.

Keyword

Carcinoma, Hepatocellular; TACE; Radiotherapy; Hepatic Resection

MeSH Terms

Adult
Aged
Antineoplastic Agents/therapeutic use
Carcinoma, Hepatocellular/radiotherapy/surgery/*therapy
*Chemoembolization, Therapeutic
Combined Modality Therapy
Doxorubicin/therapeutic use
Female
Humans
Liver/*surgery
Liver Neoplasms/radiotherapy/surgery/*therapy
Male
Middle Aged
Neoplasm Staging
Preoperative Care
Prognosis
Retrospective Studies
Severity of Illness Index
Survival Rate

Figure

• 

  Fig. 1 Overall survival curve of the 16 patients.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001. 94:153–156.

2. Annual report on the cause of death statistics. Korean statistical information system. Available at:http://kosis.kr.

3. Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S. Hepatic resection for hepatocellular carcinoma--Japanese experience. Hepatogastroenterology. 1998. 45:1267–1274.

4. Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K. Hepatic resection for hepatocellular carcinoma. Surgery. 1990. 107:511–520.

5. Kim SS, Lee CD, Choi SW, Han NI, Kim JI, Han SW, Yoon SK, Yang JM, Park YM, Han SW, Lee YS, Park DH, Kim BS. Prognosis and prognostic factors in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Gastroenterol. 1997. 30:72–80.

6. Uchida M, Kohno H, Kubota H, Hayashi T, Yamanoi A, Kimoto T, Ono T, Nagasue N. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg. 1996. 20:326–331.

7. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997. 226:688–701.

8. Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiquro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, Koyama H, Iwanaga T. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987. 60:1194–1203.

9. Dhir V, Swaroop VS, Mohandas KM, Dinshaw KA, Desai DC, Nagral A, Jagannath P, Desouza LJ. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am J Clin Oncol. 1992. 15:304–307.

10. Epstein B, Ettinger D, Leichner PK, Order SE. Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma. Cancer. 1991. 67:896–900.

11. Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, Tang AM. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001. 233:236–241.

12. Ku Y, Iwasaki T, Tominaga M, Fukumoto T, Takahashi T, Kido M, Ogata S, Takahashi M, Kuroda Y, Matsumoto S, Obara H. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg. 2004. 239:53–60.

13. Makuuchi M. Liver Cancer Study Group of Japan: Stage. The general rules for the clinical and pathological study of primary liver cancer. 2000. 4th Ed. Tokyo: Kanahara and Co;19.

14. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol. 2001. 74:983–986.

15. Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000. 7:490–495.

16. Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A, Nakamura T, Yukaya H. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery. 1989. 106:81–86.

17. Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol. 2006. 32:773–779.

18. Lu CD, Peng SY, Jiang XC, Chiba Y, Tanigawa N. Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas: retrospective analysis of 120 cases. World J Surg. 1999. 23:293–300.

19. Gotohda N, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Furuse J, Ishii H, Yoshino M. New indication for reduction surgery in patients with advanced hepatocellular carcinoma with major vascular involvement. World J Surg. 2006. 30:431–438.

20. Guo WJ, YU EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol. 2003. 9:1697–1701.

21. Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. J Gastroenterol Hepatol. 2001. 16:883–889.

22. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 1999. 43:393–397.

23. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005. 25:1189–1196.

24. Zhou ZH, Liu LM, Chen WW, Men ZQ, Lin JH, Chen Z, Zhang XJ, Jiang GL. Combined therapy of transcatheter arterial chemoembolization and three dimensional-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol. 2007. 80:194–201.

25. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J radiat Oncol Biol Phys. 2003. 57:113–119.

26. Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg. 1995. 224:4–9.

27. Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg. 2007. 31:2370–2377.

28. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer. 1993. 72:3593–3598.

29. Liou TC, Shih SC, Kao CR, Chou SY, Lin SC, Wang HY. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol. 1995. 23:563–568.

30. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000. 231:544–551.

31. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, Yang PS, You DL, Jian JJ, Tsai SY, Sung JL, Horng CF. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000. 47:435–442.